Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR: ABVD vs A2VD in Stage IA/IIA Hodgkin Lymphoma
NCT04685616Phase 3Recruiting
- Sponsor
- University College London
- Start
- Apr 2022
- Primary completion
- Sep 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University College London. Primary endpoint: Progression-Free Survival at 3 years. Started Apr 2022; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04685616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685616.